| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ... Journal of clinical oncology 36 (17), 1714-1768, 2018 | 3459 | 2018 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of clinical oncology 39 (36), 4073-4126, 2021 | 769 | 2021 |
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ... Clinical cancer research 18 (22), 6373-6383, 2012 | 575 | 2012 |
| PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ... Journal of clinical oncology 30 (8), 777, 2012 | 517 | 2012 |
| PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors F Janku, AM Tsimberidou, I Garrido-Laguna, X Wang, R Luthra, DS Hong, ... Molecular cancer therapeutics 10 (3), 558-565, 2011 | 429 | 2011 |
| A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan, A Naing, ... Cell 183 (2), 347-362. e24, 2020 | 418 | 2020 |
| Targeting the indoleamine 2, 3-dioxygenase pathway in cancer YW Moon, J Hajjar, P Hwu, A Naing Journal for immunotherapy of cancer 3, 1-10, 2015 | 347 | 2015 |
| Combining radiation and immunotherapy: a new systemic therapy for solid tumors? C Tang, X Wang, H Soh, S Seyedin, MA Cortez, S Krishnan, E Massarelli, ... Cancer immunology research 2 (9), 831-838, 2014 | 312 | 2014 |
| PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials F Janku, JJ Wheler, A Naing, GS Falchook, DS Hong, VM Stepanek, S Fu, ... Cancer research 73 (1), 276-284, 2013 | 310 | 2013 |
| Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells C Tang, JW Welsh, P De Groot, E Massarelli, JY Chang, KR Hess, S Basu, ... Clinical Cancer Research 23 (6), 1388-1396, 2017 | 298 | 2017 |
| Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center M Ayala-Ramirez, S Jasim, L Feng, S Ejaz, F Deniz, N Busaidy, ... European journal of endocrinology 169 (6), 891-899, 2013 | 282 | 2013 |
| Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors F Janku, DS Hong, S Fu, SA Piha-Paul, A Naing, GS Falchook, ... Cell reports 6 (2), 377-387, 2014 | 272 | 2014 |
| Cancer therapy directed by comprehensive genomic profiling: a single center study JJ Wheler, F Janku, A Naing, Y Li, B Stephen, R Zinner, V Subbiah, S Fu, ... Cancer research 76 (13), 3690-3701, 2016 | 253 | 2016 |
| A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas DS Hong, R Kurzrock, JG Supko, X He, A Naing, J Wheler, D Lawrence, ... Clinical cancer research 18 (12), 3396-3406, 2012 | 244 | 2012 |
| FGFR a promising druggable target in cancer: Molecular biology and new drugs R Porta, R Borea, A Coelho, S Khan, A Araújo, P Reclusa, T Franchina, ... Critical reviews in oncology/hematology 113, 256-267, 2017 | 242 | 2017 |
| PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers F Janku, JJ Lee, AM Tsimberidou, DS Hong, A Naing, GS Falchook, S Fu, ... PloS one 6 (7), e22769, 2011 | 235 | 2011 |
| Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors A Naing, KP Papadopoulos, KA Autio, PA Ott, MR Patel, DJ Wong, ... Journal of Clinical Oncology 34 (29), 3562, 2016 | 232 | 2016 |
| Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors A Naing, P LoRusso, S Fu, DS Hong, P Anderson, RS Benjamin, J Ludwig, ... Clinical Cancer Research 18 (9), 2625-2631, 2012 | 229 | 2012 |
| BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer GS Falchook, M Millward, D Hong, A Naing, S Piha-Paul, ... Thyroid 25 (1), 71-77, 2015 | 225 | 2015 |
| Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses AM Tsimberidou, S Wen, DS Hong, JJ Wheler, GS Falchook, S Fu, ... Clinical cancer research 20 (18), 4827-4836, 2014 | 222 | 2014 |
Razelle Kurzrock, MDProfessor of Medicine, Medical College of WisconsinVerified email at mcw.edu
